Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

Todd Neale

May 18, 2021

News Conference News ACC 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

Todd Neale

May 17, 2021

Presentation ACC 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presenter: Adam DeVore

May 17, 2021

Presentation ACC 2021

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

Presenter: Deepak L. Bhatt

May 17, 2021

News Conference News ACC 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

Caitlin E. Cox

May 16, 2021

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Shelley Wood

May 16, 2021

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

L.A. McKeown

May 15, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

Advertisement

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

‘Enormous’ QoL Improvements With Mavacamten in HCM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content